NEW YORK (GenomeWeb News) – VolitionRx today announced an agreement with Hvidovre Hospital, part of the University of Copenhagen in Denmark, covering two clinical trials for colorectal cancer.

As part of the deal, VolitionRx said that it will use data from the trials to support its application for CE marking and a submission to the US Food and Drug Administration for a colorectal cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.